MYC and cancer: Since MYC-KD induces the expression of the platelet-derived growth factor receptor beta (PDGFRβ), VEGFR2, and platelet-derived growth factor subunit B (PDGFB) and increased tyrosine phosphorylation of PDGFRβ, VEGFR2, HER3, and AXL in the TNBC cell line SUM159PT [168], the degradation of MYC by kinase inhibition causes resistance of cancer cells to the inhibition.